- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD0754, AZD2287
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Prostate Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 13, 2026 Report an issue
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Prostate Cancer studies are organized in the registry
Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Prostate Cancer
- Interventions
- Stereotactic Ablative Radiotherapy
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
- Radiation · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- LEAD RT, HEIGHT RT
- Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 35 Years to 85 Years · Male only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- Observation, Glycyrrhizin - 75 mg, Glycyrrhizin - 150 mg
- Other · Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- [18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1
- Device · Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Recurrent Prostate Carcinoma
- Interventions
- High-Dose Rate Brachytherapy, Hyperthermia Treatment, Laboratory Biomarker Analysis
- Radiation · Procedure · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
- Interventions
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
- Interventions
- Abiraterone acetate, Dexamethasone, Metronidazole
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- STM-416p
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Gainesville, Florida
- Conditions
- Prostate Cancer
- Interventions
- Lower-Carbohydrate Med-t-Diet, Low-Fat Med-t-Diet
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
About this Prostate Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Prostate Cancer.